Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Core Viewpoint - Dyadic International, Inc. is transitioning from a technology development organization to a market-facing, revenue-focused biotechnology company, with significant advancements in its life sciences and nutrition pipelines, and a recent capital raise to support this shift [2][4]. Company Developments and Updates - The company completed a strategic leadership and operational transformation, rebranding as Dyadic Applied BioSolutions to emphasize commercial execution [4]. - Dyadic raised $5.3 million through an equity offering to enhance liquidity and fund pipeline and commercial growth [4][11]. - As of June 30, 2025, the company reported cash and equivalents of $7.3 million, down from $9.3 million at the end of 2024 [10]. Financial Highlights - Total revenue for Q2 2025 reached $967,000, a significant increase from $386,000 in the same period last year, driven by milestone revenues [12][13]. - Research and development expenses rose to $629,000 from $516,000 year-over-year, reflecting increased internal research initiatives [14]. - General and administrative expenses decreased by 10.6% to $1,437,000 compared to $1,608,000 in the previous year [15]. - The net loss for Q2 2025 was $1,794,000, an improvement from a net loss of $2,045,000 in the same quarter of the previous year [17]. Product Development and Partnerships - Dyadic is advancing its recombinant serum albumin and transferrin products, with expected commercial launches in 2025 [5]. - The company is also developing additional nucleic acid enzymes to meet growing demand for DNA/RNA manipulation tools, with results anticipated by late 2025 [6]. - Dyadic has achieved milestones in its partnership with the Gates Foundation, receiving $1.5 million in funding for monoclonal antibody development [12]. Market Focus - Dyadic's microbial production platforms are positioned to disrupt the cost, speed, and scalability of protein production across various markets, particularly as industries shift towards non-animal sources [2][4]. - The company is actively negotiating licensing and supply agreements for its recombinant alpha-lactalbumin and expects to launch additional non-animal dairy enzymes by late 2025 [12].